Gamze Beydağı

Gamze Beydağı

Auto-generated profile, based on publicly available information

Gamze Beydağı

Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
EDemre demirci
emre demirci
NSNalan Alan Selçuk
Nalan Alan Selçuk
GBGamze Beydağı
Gamze Beydağı
MOMeltem Ocak
Meltem Ocak
TTTürkay Toklu
Türkay Toklu
LKLevent Kabasakal
Levent Kabasakal
This study aimed to evaluate the stability, safety, and efficacy of alpha-targeted therapy with [225Ac]Ac-DOTATATE in patients with grade 1/2 metastatic neuroendocrine tumors (NETs). This retrospective cohort included patients (n=11) with metastatic NETs from different primary sites (bronchial, pancreatic, nonpancreatic gastroenteropancreatic NETs, paraganglioma, and unknown primary site) treated with [225Ac]Ac-DOTATATE with a mean activity of 8.2±0.6 MBq (range: 7.5-10.0 MBq) at our institution between November 2019 and March 2022. The in vivo and in vitro stability of [225Ac]Ac-DOTATATE was calculated. The safety profile was evaluated according to the CTCAE-v5.0. Treatment efficacy was evaluated according to [68Ga] Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) images and the RECIST 1.1 criteria. Patients had 73% (n=8) lymph node metastases, 91% (n=10) liver metastases, 36% (n=4) lung metastases, and 73% (n=8) bone metastases. All but one patient was refractory to treatment with [177Lu]Lu-DOTATATE. [225Ac]Ac-DOTATATE was stable for at least 5 h in vitro (in saline) and 3 h in vivo (urine and blood samples). Grade 2 renal toxicity and grade 2 hematotoxicity were observed in one patient. No grade 3-4 toxicities were reported. According to post-treatment [68Ga]Ga-DOTATATE PET/CT (n=9), 11% (n=1) had progressive disease, 44.4% (n=4) had stable disease, and 44.4% (n=4) had a partial response. The disease control rate was 89% (n=8). The median progression-free survival estimated according to Kaplan-Meier analysis was 12 months. The preliminary results of this study suggest that [225Ac]Ac-DOTATATE is stable, safe, and effective for treating advanced and [177Lu] Lu-DOTATATE-refractory NETs. However, prospective studies are needed to determine the impact of treatment on overall survival and to uncover potential side effects.

19 December 2023 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
KAKaan Akcay
Kaan Akcay
AKAli Kibar
Ali Kibar
OSOnur Erdem Sahin
Onur Erdem Sahin
MDMuhammet Demirbilek
Muhammet Demirbilek
GBGamze Beydagi
Gamze Beydagi
LKLevent Kabasakal
Levent Kabasakal

7 February 2025 in Molecular Imaging and Radionuclide Therapy
Verified
Journal Article
Open access
NSNalan Alan Selçuk
Nalan Alan Selçuk
GBGamze Beydağı
Gamze Beydağı
KAKaan Akçay
Kaan Akçay
EDemre demirci
emre demirci
AGAyşegül Görmez
Ayşegül Görmez
LKLevent Kabasakal
Levent Kabasakal
Impact of 68Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal 18F-FDG PET/CT Findings - Molecular Imaging and Radionuclide Therapy

6 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OKOğuzcan Kınıkoğlu
Oğuzcan Kınıkoğlu
BObasak oven
basak oven
SÇSerkan Çelik
Serkan Çelik
NSNalan Alan Selçuk
Nalan Alan Selçuk
GBGamze Beydağı
Gamze Beydağı
LKLevent Kabasakal
Levent Kabasakal
Background: The combination of Lutetium-177 (Lu-177) PSMA-617 radioligand therapy (RLT) with androgen receptor pathway inhibitors (ARPIs) has shown promise in metastatic castration-resistant prostate cancer (mCRPC). However, real-world data on the efficacy and safety of this combination are limited. This study aimed to evaluate the impact of combination therapy with Lu-177 PSMA-617 RLT and ARPIs on progression-free survival (PFS) and overall survival (OS) in patients with mCRPC. Methods: In this retrospective study, 104 mCRPC patients receiving Lu-177 PSMA-617 RLT at our institution between December 2017 and January 2024 were divided into the following two groups those receiving Lu-177 PSMA-617 RLT plus ARPI (n = 34) and those receiving Lu-177 PSMA-617 RLT alone (n = 70). Patients received 150 to 200 millicuries Lu-177 PSMA-617 RLT in each cycle. PFS and zOS were assessed using Kaplan–Meier analysis and Cox proportional hazard models. Results: The combination therapy significantly prolonged median PFS compared to Lu-177 PSMA-617 RLT alone (11 vs. 5.6 months; HR, 0.47; 95% CI, 0.28–0.79; p < 0.01). A trend towards improved OS was also observed in the combination group (20.3 vs. 15.9 months; HR, 0.58; 95% CI, 0.33–1.02; p = 0.06). Age was a significant predictor of OS (21.2 vs. 12.4 months for younger vs. older patients; p < 0.01), while Gleason score and visceral involvement did not significantly impact PFS. The safety profile indicated that adverse effects were generally comparable between the two groups, with no statistically significant differences in the incidence of anemia, neutropenia, thrombocytopenia, nephrotoxicity, or hepatotoxicity. Conclusions: This study provides evidence that combining Lu-177 PSMA-617 RLT with ARPIs may significantly improve PFS in mCRPC patients. The potential OS benefit warrants further investigation in larger prospective trials. Age should be considered when making treatment decisions for mCRPC patients.

29 April 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
NANalan Alan-Selcuk
Nalan Alan-Selcuk
KAKaan Akcay
Kaan Akcay
GBGamze Beydagi
Gamze Beydagi
RAResit Akyel
Resit Akyel
TTTurkay Toklu
Turkay Toklu
LKLevent Kabasakal
Levent Kabasakal

30 September 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
NSNalan Alan Selcuk
Nalan Alan Selcuk
GBGamze Beydagi
Gamze Beydagi
KAKaan Akcay
Kaan Akcay
AGAyşegul Gormez
Ayşegul Gormez
TTTurkay Toklu
Turkay Toklu
LKLevent Kabasakal
Levent Kabasakal